Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 57 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dyspareunia (Female) Clear all
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

NCT00318500
View directory record Official record
Conditions
Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
49
States / cities
Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Phase 4 Interventional

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

NCT03568604
View directory record Official record
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Acupuncture for Vulvodynia: A Pre-pilot Study

NCT02704234
View directory record Official record
Conditions
Vulvodynia, Vulvar Vestibulitis, Dyspareunia, Pain
Interventions
Active Acupuncture, Placebo Acupuncture
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Wilmette, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

NCT02253173
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
Interventions
Estradiol, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Huntsville, Alabama • Montgomery, Alabama • Mesa, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treating Postmenopausal Dyspareunia Where it Hurts

NCT03240081
View directory record Official record
Conditions
Dyspareunia
Interventions
50mcg estradiol cream, 100mcg estradiol cream
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Fractional CO2 Laser Therapy for Survivors of Breast Malignancies

NCT03307044
View directory record Official record
Conditions
Breast Carcinoma, Cancer Survivor, Cervical Carcinoma, Dyspareunia, Vaginal Dryness
Interventions
Laser Therapy, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Life-Stress Interview for Women With Chronic Urogenital Pain Conditions

NCT02286115
View directory record Official record
Conditions
Chronic Urogenital Pain
Interventions
Life-Stress Interview
Behavioral
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 3, 2026, 9:59 PM EDT
Not listed Phase 4 Interventional

Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain

NCT02022722
View directory record Official record
Conditions
Dyspareunia
Interventions
Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride, Pelvic Rehabilitation
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Acupuncture for the Treatment of Vulvodynia

NCT02197429
View directory record Official record
Conditions
Vulvodynia, Vulvar Vestibulitis, Pain, Dyspareunia, Female Sexual Dysfunction Due to Physical Condition
Interventions
Acupuncture
Other
Lead sponsor
Schlaeger, Judith M., CNM, LAc, PhD
Individual
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Phase 2 Interventional

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

NCT02150525
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
Interventions
omega-3 fatty acid, placebo, Questionnaire administration
Dietary Supplement · Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 3, 2026, 9:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

VEDA Study (DHEA vs Estradiol)

NCT07574216
View directory record Official record
Conditions
Post-menopause, Pre-menopause, Sexual Function, Menopause, Vaginal Dryness, Painful Intercourse
Interventions
DHEA ovals, Estradiol 0.01% Vag Cream
Drug
Lead sponsor
University of Arizona
Other
Eligibility
40 Years to 90 Years · Female only
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Early Phase 1 Interventional

Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness

NCT02029053
View directory record Official record
Conditions
Menopausal and Perimenopausal Disorder, Unspecified, Atrophic Vaginitis
Interventions
Vaginal Lubrication Ring for Vaginal Dryness
Device
Lead sponsor
J3 Bioscience, Inc.
Industry
Eligibility
35 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 3, 2026, 9:59 PM EDT
Withdrawn Not applicable Interventional

Vaginal Dilator Therapy Among Women With Gynecologic and Breast Cancers Experiencing Dyspareunia

NCT05129332
View directory record Official record
Conditions
Dyspareunia
Interventions
Vaginal Moisturizer, Vaginal Dilator
Other · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 3, 2026, 9:59 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors

NCT03257670
View directory record Official record
Conditions
Dyspareunia
Interventions
4% Topical Lidocaine Gel, CO2RE fractional laser therapy
Drug · Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

NCT01845649
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 3, 2026, 9:59 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

NCT03986944
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
107
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

The Vaginal Health Trial

NCT02516202
View directory record Official record
Conditions
Atrophy of Vagina, Menopause, Dyspareunia (Female)
Interventions
Vagifem, Replens, Placebo tablet, Placebo gel
Drug · Device · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 3, 2026, 9:59 PM EDT
Not listed Phase 4 Interventional

Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome

NCT01312259
View directory record Official record
Conditions
Painful Bladder Syndrome, Interstitial Cystitis, Pelvic Floor; Insufficiency, Bowel Dysfunction, Sexual Dysfunction, Pelvic Floor; Incompetency
Interventions
Changing the Interstim parameter of '' Frequency" in patients with Interstitial Cystitis
Other
Lead sponsor
Pelvic and Sexual Health Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 3, 2026, 9:59 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Mollie Study, a Study to Evaluate the Safety and Efficacy of the Mollie Medical Device

NCT05445115
View directory record Official record
Conditions
Dyspareunia
Interventions
Mollie device
Device
Lead sponsor
JSP Innovations
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Decatur, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause

NCT03178825
View directory record Official record
Conditions
Vaginal Atrophy, Sexual Dysfunction, Dyspareunia, Vaginal Dryness, Chronic UTI
Interventions
Hybrid Fractional Laser
Device
Lead sponsor
Sciton
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Gatos, California • Pensacola, Florida • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Phase 3 Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

NCT00196378
View directory record Official record
Conditions
Menopause
Interventions
Synthetic Conjugated estrogens, B, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2013 · Synced Oct 3, 2026, 9:59 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study of Participants Ages 21-65 Diagnosed With Dyspareunia and the Effects of Low Intensity Shockwave Treatment

NCT05806203
View directory record Official record
Conditions
Female Dyspareunia
Interventions
Low intensity shockwave treatment to pelvic floor region plus typical physical therapy, Sham shockwave treatment plus typical physical therapy
Device
Lead sponsor
SoftWave Tissue Regeneration Technologies
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Botox Injection for Treatment of Vaginismus

NCT01352546
View directory record Official record
Conditions
Vaginismus
Interventions
BOTOX
Biological
Lead sponsor
Plastic Surgery Professional Association
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 3, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

NCT02778399
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, OBE2109
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
71
States / cities
Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 3, 2026, 9:59 PM EDT